Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients

• Published in: Pharmacogenomics Vol. 22; no. 15; pp. 1019 - 1040
• Main Authors: Jiang, Zhenwei, Hu, Nan
• Format: Journal Article
• Language: English
• Published: England 01-10-2021
• Subjects: Glucuronosyltransferase - genetics; Glucuronosyltransferase - metabolism; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - pharmacokinetics; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - methods; Mycophenolic Acid - adverse effects; Mycophenolic Acid - pharmacokinetics; Mycophenolic Acid - therapeutic use; Polymorphism, Genetic - genetics; Polymorphism, Single Nucleotide; Transplant Recipients; UGT polymorphism; pharmacokinetics; metabolites; adverse reactions; kidney transplantation; mycophenolic acid
• ISSN: 1462-2416; 1744-8042
• DOI: 10.2217/pgs-2021-0087

Mycophenolic acid (MPA) is a common immunosuppressive drug for kidney transplantation patients, and is characterized by a narrow therapeutic index and significant individual variability. UGTs are the main enzymes responsible for the metabolism of MPA. Although, many studies have focused on the relationship between
polymorphisms and pharmacokinetics and adverse reactions of MPA, the conclusion are controversial. We reviewed the relevant literature and summarized the significant influences of
polymorphisms, such as
(rs1042597, rs17863762),
(rs72551330, rs6714486, rs17868320, rs2741045, rs2741045) and
(rs7438135, rs7439366, rs7662029), on the pharmacokinetics of MPA and its metabolites and adverse reactions. The review provides a reference for guiding the individualized administration of MPA and reducing adverse reactions to MPA.